floxuridine has been researched along with Pancreatic Neoplasms in 37 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluorine-19 NMR spectrometry was used to monitor the metabolism of two antineoplastic fluoropyrimidines, 5-fluorouracil (5FU) and 5'-deoxy-5-fluorouridine (5'dFUrd), in cell cultures of human pancreatic (Capan-1) and colon (HT-29) adenocarcinoma." | 7.67 | Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma. ( Faure, F; Hollande, E; Malet-Martino, MC; Martino, R; Palevody, C; Vialaneix, JP, 1986) |
| "Gemcitabine (dFdC) is a prodrug that undergoes metabolism by cytidine deaminase to form an inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU)." | 5.31 | Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. ( Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG, 2000) |
| "Floxuridine is a clinically proven anticancer agent in the treatment of metastatic colon carcinomas and hepatic metastases." | 3.73 | Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. ( Amidon, GL; Landowski, CP; Song, X; Vig, BS, 2005) |
| "Fluorine-19 NMR spectrometry was used to monitor the metabolism of two antineoplastic fluoropyrimidines, 5-fluorouracil (5FU) and 5'-deoxy-5-fluorouridine (5'dFUrd), in cell cultures of human pancreatic (Capan-1) and colon (HT-29) adenocarcinoma." | 3.67 | Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma. ( Faure, F; Hollande, E; Malet-Martino, MC; Martino, R; Palevody, C; Vialaneix, JP, 1986) |
| " In our previous studies with human gastrointestinal and breast cancers xenografted into nude mice, combination therapy with mitomycin C (MMC) and 5'-deoxy-5-fluorouridine (5'-DFUR) [I] or cisplatin (CDDP), vindesine (VDS) and 5'-DFUR [II] produced higher response rates than single-agent therapy with any one of these drugs." | 3.67 | [Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice]. ( Fujita, F; Fujita, M; Inaba, H; Sakamoto, Y; Shimozuma, K; Taguchi, T; Yamauchi, T, 1987) |
| "Gemcitabine 1,000 mg/m(2) was infused over 100 min (days 1, 8 and 15)." | 2.73 | Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study. ( Bang, SJ; Joo, KR; Kim, H; Kim, MJ; Min, YJ; Nah, YW; Nam, CW; Park, JH; Park, NH; Shin, SJ, 2008) |
| "Gemcitabine accumulation was significantly enhanced in fibroblast-rich tumours compared with liver metastases and normal liver." | 1.48 | Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. ( Bapiro, TE; Chen, N; Ellenrieder, V; Frese, KK; Gopinathan, A; Gress, TM; Hessmann, E; Heuchel, R; Jodrell, DI; Johnsen, SA; Kari, V; Klein, L; Li, X; Löhr, JM; Neesse, A; Patzak, MS; Ramu, I; Richards, FM; Verbeke, C, 2018) |
| "Several factors may influence pancreatic cancer resistance, and expression of ATP-binding cassette transport proteins is one of the major mechanisms of drug resistance." | 1.37 | Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. ( Grube, M; Guitton, J; Hübner, T; Jedlitschky, G; Köck, K; Kowalczyk, DW; Kroemer, HK; Lerch, MM; Mayerle, J; Mews, S; Nambaru, PK; Payen, L; Rimmbach, C; Ritter, CA; Rosskopf, D; Sendler, M; Weiss, FU, 2011) |
| " The pharmacokinetic analysis of gemcitabine and dFdU was performed with high-performance liquid chromatography-tandem mass spectrometry assay in cycles 1 and 2." | 1.35 | Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function. ( Citro, G; Cognetti, F; Colantonio, S; Contestabile, M; Di Segni, S; Felici, A; Milella, M; Nuvoli, B; Sacconi, A; Sperduti, I; Zaratti, M, 2009) |
| "Experimentally, we studied a diploid colorectal cancer line heterozygous at TS to mimic three common TS genotypes of cancers." | 1.33 | Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy. ( Brody, JR; Gallmeier, E; Hucl, T; Kern, SE; Murphy, KM; Winter, JM, 2006) |
| "Gemcitabine (dFdC) is a prodrug that undergoes metabolism by cytidine deaminase to form an inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU)." | 1.31 | Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. ( Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG, 2000) |
| "Animals with pancreatic cancer displayed focal uptake of both tracers." | 1.31 | In vivo evaluation of 5-[(18)F]fluoro-2'-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model. ( Glatting, G; Greten, FR; Neumaier, B; Reske, SN; Schmid, RM; Seitz, U; Vogg, AT; Wagner, M, 2001) |
| "Invest, 101: 344-352, 1998) to suppress pancreatic cancer cell growth and increase cytotoxic actions of cisplatinum." | 1.30 | Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. ( Arber, N; Beger, HG; Danenberg, KD; Danenberg, PV; Korc, M; Kornmann, M, 1999) |
| "Doxifluridine (5-DFUR) is an orally active fluoropyrimidine, and its cytotoxic metabolite (5-FU) may concentrate in areas of high tumor vascularization." | 1.30 | Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study. ( Artale, S; Bajetta, E; Bozzetti, F; Buzzoni, R; Di Bartolomeo, M; Mazzaferro, V; Ricci, SB; Stani, SC; Toffolatti, L, 1999) |
| "Three patients with primary hepatocellular carcinoma demonstrated less than 50% reduction in tumor size." | 1.27 | Assessment of treatment of intrahepatic malignancies using chemotherapy via an implantable pump. ( Jones, LS; McCune, CS; Schwartz, SI, 1985) |
| "Although advanced gastrointestinal cancer is the most commonplace problem encountered by the medical oncologist, this group of diseases has proved exceedingly resistant to past chemotherapy efforts." | 1.25 | Clinical management of advanced gastrointestinal cancer. ( Moertel, CG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (40.54) | 18.7374 |
| 1990's | 4 (10.81) | 18.2507 |
| 2000's | 11 (29.73) | 29.6817 |
| 2010's | 7 (18.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nambaru, PK | 1 |
| Hübner, T | 1 |
| Köck, K | 1 |
| Mews, S | 1 |
| Grube, M | 1 |
| Payen, L | 1 |
| Guitton, J | 1 |
| Sendler, M | 1 |
| Jedlitschky, G | 1 |
| Rimmbach, C | 1 |
| Rosskopf, D | 1 |
| Kowalczyk, DW | 1 |
| Kroemer, HK | 1 |
| Weiss, FU | 1 |
| Mayerle, J | 1 |
| Lerch, MM | 1 |
| Ritter, CA | 1 |
| Han, H | 1 |
| Wang, J | 1 |
| Chen, T | 1 |
| Yin, L | 1 |
| Jin, Q | 1 |
| Ji, J | 1 |
| Hessmann, E | 1 |
| Patzak, MS | 1 |
| Klein, L | 1 |
| Chen, N | 1 |
| Kari, V | 1 |
| Ramu, I | 1 |
| Bapiro, TE | 1 |
| Frese, KK | 1 |
| Gopinathan, A | 1 |
| Richards, FM | 1 |
| Jodrell, DI | 1 |
| Verbeke, C | 1 |
| Li, X | 1 |
| Heuchel, R | 1 |
| Löhr, JM | 1 |
| Johnsen, SA | 1 |
| Gress, TM | 1 |
| Ellenrieder, V | 1 |
| Neesse, A | 1 |
| Felici, A | 1 |
| Di Segni, S | 1 |
| Milella, M | 1 |
| Colantonio, S | 1 |
| Sperduti, I | 1 |
| Nuvoli, B | 1 |
| Contestabile, M | 1 |
| Sacconi, A | 1 |
| Zaratti, M | 1 |
| Citro, G | 1 |
| Cognetti, F | 1 |
| Ohmine, K | 1 |
| Kawaguchi, K | 1 |
| Ohtsuki, S | 1 |
| Motoi, F | 1 |
| Egawa, S | 1 |
| Unno, M | 1 |
| Terasaki, T | 1 |
| Tsume, Y | 1 |
| Amidon, GL | 2 |
| Ji, S | 1 |
| Xu, J | 1 |
| Zhang, B | 1 |
| Xu, Y | 1 |
| Liu, C | 1 |
| Long, J | 1 |
| Ni, Q | 1 |
| Yu, X | 1 |
| Patel, K | 1 |
| Yerram, SR | 1 |
| Azad, NA | 1 |
| Kern, SE | 2 |
| Takizawa, M | 1 |
| Hirano, M | 1 |
| Murakami, N | 1 |
| Uno, Y | 1 |
| Kikuchi, T | 1 |
| Nozawa, H | 1 |
| Hara, T | 1 |
| Asaumi, Y | 1 |
| Kikkawa, H | 1 |
| Shibamoto, Y | 1 |
| Mimasu, Y | 1 |
| Tachi, Y | 1 |
| Hatta, H | 1 |
| Nishimoto, S | 1 |
| SULLIVAN, RD | 3 |
| NORCROSS, JW | 1 |
| WATKINS, E | 1 |
| CLIFTON, KH | 1 |
| SZYBALSKI, W | 1 |
| HEIDELBERGER, C | 1 |
| GOLLIN, FF | 1 |
| ANSFIELD, FJ | 2 |
| VERMUND, H | 1 |
| ZUREK, WZ | 1 |
| Ardalan, B | 1 |
| Lima, M | 1 |
| Chung, HW | 1 |
| Bang, SM | 1 |
| Park, SW | 1 |
| Chung, JB | 1 |
| Kang, JK | 1 |
| Kim, JW | 1 |
| Seong, JS | 1 |
| Lee, WJ | 1 |
| Song, SY | 1 |
| Landowski, CP | 1 |
| Vig, BS | 1 |
| Song, X | 1 |
| Brody, JR | 1 |
| Hucl, T | 1 |
| Gallmeier, E | 1 |
| Winter, JM | 1 |
| Murphy, KM | 1 |
| Kim, H | 1 |
| Park, JH | 1 |
| Shin, SJ | 1 |
| Kim, MJ | 1 |
| Bang, SJ | 1 |
| Park, NH | 1 |
| Nah, YW | 1 |
| Nam, CW | 1 |
| Joo, KR | 1 |
| Min, YJ | 1 |
| Sommadossi, JP | 2 |
| Aubert, C | 1 |
| Cano, JP | 2 |
| Gouveia, J | 1 |
| Ribaud, P | 1 |
| Mathé, G | 1 |
| Armstrong, RD | 1 |
| Gesmonde, J | 1 |
| Wu, T | 1 |
| Cadman, E | 1 |
| Chu, MY | 1 |
| Naguib, FN | 1 |
| Iltzsch, MH | 1 |
| el Kouni, MH | 1 |
| Chu, SH | 1 |
| Cha, S | 1 |
| Calabresi, P | 1 |
| Matsuoka, H | 1 |
| Seo, Y | 1 |
| Ohshiro, T | 1 |
| Adachi, E | 1 |
| Nagamine, S | 1 |
| Miyazaki, N | 1 |
| Shiromizu, A | 1 |
| Baba, H | 1 |
| Kounoe, S | 1 |
| Saito, T | 1 |
| Robertson, JM | 1 |
| Shewach, DS | 1 |
| Lawrence, TS | 1 |
| Kornmann, M | 1 |
| Danenberg, KD | 1 |
| Arber, N | 1 |
| Beger, HG | 1 |
| Danenberg, PV | 1 |
| Korc, M | 1 |
| Bajetta, E | 1 |
| Di Bartolomeo, M | 1 |
| Stani, SC | 1 |
| Artale, S | 1 |
| Ricci, SB | 1 |
| Bozzetti, F | 1 |
| Mazzaferro, V | 1 |
| Toffolatti, L | 1 |
| Buzzoni, R | 1 |
| Delauter, BJ | 1 |
| Ramanathan, RK | 1 |
| Egorin, MJ | 1 |
| Stover, LL | 1 |
| Zuhowski, EG | 1 |
| Plunkett, W | 1 |
| Zamboni, WC | 1 |
| Seitz, U | 1 |
| Wagner, M | 1 |
| Vogg, AT | 1 |
| Glatting, G | 1 |
| Neumaier, B | 1 |
| Greten, FR | 1 |
| Schmid, RM | 1 |
| Reske, SN | 1 |
| Tsuruta, K | 1 |
| Okamoto, A | 1 |
| Egawa, N | 1 |
| Kamisawa, T | 1 |
| Karasawa, K | 1 |
| Takahashi, T | 1 |
| Moertel, CG | 2 |
| Schwartz, SI | 1 |
| Jones, LS | 1 |
| McCune, CS | 1 |
| Malet-Martino, MC | 1 |
| Faure, F | 1 |
| Vialaneix, JP | 1 |
| Palevody, C | 1 |
| Hollande, E | 1 |
| Martino, R | 1 |
| Fujita, F | 1 |
| Fujita, M | 1 |
| Yamauchi, T | 1 |
| Sakamoto, Y | 1 |
| Shimozuma, K | 1 |
| Inaba, H | 1 |
| Taguchi, T | 1 |
| Davis, HL | 1 |
| Ramirez, G | 1 |
| Miller, E | 1 |
| Van Dyk, JJ | 1 |
| Clarkson, BD | 1 |
| Duschinsky, R | 1 |
| Keller, O | 1 |
| La Sala, E | 1 |
| Krakoff, IH | 1 |
3 reviews available for floxuridine and Pancreatic Neoplasms
| Article | Year |
|---|---|
Management of a malignant case of solid pseudopapillary tumor of pancreas: a case report and literature review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Female; | 2012 |
Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma.
Topics: Antimetabolites, Antineoplastic; Bromodeoxyuridine; Combined Modality Therapy; Deoxycytidine; Floxur | 1996 |
Survival benefits of adjuvant chemotherapy with oral doxifluridine (5'-DFUR) following radiotherapy in patients with unresectable pancreatic cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Administra | 2001 |
4 trials available for floxuridine and Pancreatic Neoplasms
| Article | Year |
|---|---|
A phase II trial of FUdR in patients with advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Floxuridine; Humans; Pancreatic Neoplasms; Treatment Outcome | 2004 |
A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Floxuridine; Gem | 2004 |
Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D | 2008 |
[Pharmacological study of 5'-DFUR oral administration and the clinical responses against gastrointestinal carcinoma].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Sch | 1995 |
30 other studies available for floxuridine and Pancreatic Neoplasms
| Article | Year |
|---|---|
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Multiple; Drug R | 2011 |
Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment.
Topics: Albumins; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carri | 2017 |
Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.
Topics: 5'-Nucleotidase; Actins; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cel | 2018 |
Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biliary Tract Neopla | 2009 |
Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resista | 2012 |
The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme.
Topics: Amino Acids; Antimetabolites, Antineoplastic; Cathepsin B; Cathepsin D; Cell Line, Tumor; Cell Proli | 2012 |
A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing.
Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; Colorectal Neoplasms; Dose-Response Relations | 2012 |
[A case of recurrent gastric cancer that responded dramatically to docetaxel and 5'-DFUR combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr | 2002 |
Comparison of 5-fluorouracil and 5-fluoro-2'-deoxyuridine as an effector in radiation-activated prodrugs.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Colony-Forming Units Assay; Female; Floxuri | 2002 |
CHEMOTHERAPY OF METASTATIC LIVER CANCER BY PROLONGED HEPATIC-ARTERY INFUSION.
Topics: Alkaline Phosphatase; Bile Duct Neoplasms; Bilirubin; Chemotherapy, Cancer, Regional Perfusion; Colo | 1964 |
INCORPORATION OF I-125-LABELED IODODEOXYURIDINE INTO THE DEOXYRIBONUCLEIC ACID OF MURINE AND HUMAN TISSUES FOLLOWING THERAPEUTIC DOSES.
Topics: Adenocarcinoma; Animals; DNA; DNA, Neoplasm; Floxuridine; Geriatrics; Idoxuridine; Intestine, Small; | 1963 |
PROTRACTED AMBULATORY INFUSION CANCER CHEMOTHERAPY BY THE WATKINS CHRONOMETRIC INFUSOR.
Topics: Adenoma; Antineoplastic Agents; Breast Neoplasms; Carcinosarcoma; Colonic Neoplasms; Dermatitis, Exf | 1964 |
Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs.
Topics: Amino Acids; Animals; Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Line; Cell Line, Tumor; Ce | 2005 |
Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy.
Topics: 5' Untranslated Regions; Alleles; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neop | 2006 |
Kinetics and metabolism of a new fluoropyrimidine, 5'-deoxy-5-fluorouridine, in humans.
Topics: Colonic Neoplasms; Drug Evaluation; Floxuridine; Humans; Isomerism; Kinetics; Neoplasm Metastasis; P | 1983 |
Cytotoxic activity of 5'-deoxy-5-fluorouridine in cultured human tumors.
Topics: Breast Neoplasms; Cell Line; Cell Survival; Colonic Neoplasms; Drug Evaluation, Preclinical; Female; | 1983 |
Potentiation of 5-fluoro-2'-deoxyuridine antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine and benzyloxybenzylacyclouridine.
Topics: Animals; Cell Line; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Female; Floxuridine | 1984 |
Determination of a novel fluoropyrimidine, 5'-deoxy-5-fluorouridine, in plasma by high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Floxuridine; Half-Life; Humans; Infusions, Parenteral; Pancrea | 1981 |
Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes.
Topics: Adenocarcinoma; Cyclin D1; Drug Resistance, Neoplasm; Enzyme Induction; Floxuridine; Fluorouracil; G | 1999 |
Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Feasi | 1999 |
Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
Topics: Abdominal Pain; Adenocarcinoma; Antimetabolites, Antineoplastic; Ascites; Catheters, Indwelling; Chr | 2000 |
In vivo evaluation of 5-[(18)F]fluoro-2'-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model.
Topics: Animals; Cell Division; Disease Models, Animal; Disease Progression; Floxuridine; Fluorodeoxyglucose | 2001 |
Chemotherapy of gastrointestinal cancer.
Topics: Doxorubicin; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Mitomyc | 1976 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenoma, Islet Cell; Carcinoma, Hepatocellular; Carmustine; Colonic Neoplasms; Cytarabine; Drug Ther | 1975 |
Assessment of treatment of intrahepatic malignancies using chemotherapy via an implantable pump.
Topics: Adenoma, Islet Cell; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Catheterization; Catheters | 1985 |
Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma.
Topics: Adenocarcinoma; Cells, Cultured; Colonic Neoplasms; Floxuridine; Fluorine; Fluorouracil; Humans; Mac | 1986 |
[Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neopla | 1987 |
Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Bile Duct Neoplasms; Evaluation Studies as Topic; Floxuridine | 1974 |
The clinical effects of prolonged intravenous infusion of 5-fluoro-2'-deoxyuridine.
Topics: Adenoma, Islet Cell; Aged; Breast Neoplasms; Carcinoma, Squamous Cell; Colonic Neoplasms; Female; Fl | 1965 |
Clinical evaluation of 5-bromo-5-fluoro-6-methoxy-dihydro-2'-deoxyuridine.
Topics: Adenocarcinoma; Adult; Aged; Animals; Bromodeoxyuridine; Carcinoma; Carcinoma, Hepatocellular; Carci | 1967 |